NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Biotechnology · USD

Arcus Biosciences, Inc. (RCUS) Stock Analysis

Arcus Biosciences, Inc. (RCUS) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

RCUS

$29.66

−$0.47 (−1.56%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RCUS with… →

RCUS Key Statistics

As of Sep 4, 2026
Trading
Open
$29.64
Previous Close
$30.13
Day's Range
29.40–30.10
52-Week Range
11.04–31.74
Volume
737.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.81
Valuation
Market Cap
$3.73B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
31.88
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.94
Financials (FY)
Revenue (FY)
$247.00M−4.26%
Net Income (FY)
−$353.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
125.77M
1-Year Return
+156.57%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
1.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RCUS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+24.46%
2025+60.04%
2024−22.04%
2023−7.64%
2022−48.90%
2021+55.89%
2020+157.03%
2019−6.22%
2018 (partial year)−36.65%

As of September 4, 2026.

RCUS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$247.00M−$353.00M−142.9%
2024$258.00M−$283.00M−109.7%
2023$117.00M−$307.00M−262.4%
2022$112.00M−$267.00M−238.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$247.00M—−$386.00M−$353.00M−142.9%
2024$258.00M—−$310.00M−$283.00M−109.7%
2023$117.00M—−$340.00M−$307.00M−262.4%
2022$112.00M—−$280.00M−$267.00M−238.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RCUS Valuation vs Biotechnology Median

Median of 656 stocks
MetricRCUSBiotechnology medianvs median
P/S ratio31.8815.26109% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Arcus Biosciences, Inc. (RCUS) is capitalised at $3.73B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 601 employees.

The 52-week range on file runs from $11.04 to $31.74. RCUS last closed at $29.66 on September 4, 2026. That is −$0.47 (−1.56%) against the previous close. The latest close sits 168.66% above that 52-week low.

Financial Health

In fiscal 2025, Arcus Biosciences, Inc. reported revenue of $247.00M. Against the prior fiscal year total of $258.00M, that is a change of −4.26%. The same year closed with a net loss of $353.00M. The reported profit margin is 0%. Trailing earnings per share are −3.94.

Across the 4 fiscal years on file, revenue moves from $112.00M in 2022 to $247.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 31.88 times revenue. On price-to-sales that is 108.89% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.81. Annualized volatility over the trailing 8 years is 76.8%. The trailing one-year price return is +156.57%. Across 5 years the annualized return works out at −2.36%.

Growth & Income

The record shows no dividend for RCUS.

2026 is still running; the price is +24.46% year to date. The strongest complete calendar year on file is 2020 at +157.03%; the weakest is 2022 at −48.90%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Arcus Biosciences, Inc. (RCUS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arcus Biosciences, Inc. RCUS $3.73B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Arcus Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Visit website →